Rohatgi Pooja R, Swisher Stephen G, Correa Arlene M, Wu Tsung T, Liao Zhongxing, Komaki Ritsuko, Walsh Garrett L, Vaporciyan Ara A, Rice David C, Bresalier Robert S, Roth Jack A, Ajani Jaffer A
Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2006 Feb 1;106(3):552-8. doi: 10.1002/cncr.21601.
The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology.
The authors stratified patients by adenocarcinoma (ACA) or squamous cell carcinoma (SCC) and compared the overall survival (OS) and patterns of failure among patients achieving pathologic complete response (pathCR) and <pathCR after preoperative CTRT. A correlation between baseline clinical stage and posttherapy pathologic response was made for ACA and SCC.
Of the 235 patients who underwent preoperative CTRT, 42 (18%) had SCC and 193 (82%) had ACA. In the ACA group, 56 patients (29%) achieved a pathCR and in the SCC group 13 patients (31%) achieved a pathCR. In the ACA group, a larger proportion of pathCR patients (n=44; 79%) than <pathCR patients (n=82; 60%) were alive at the time of last follow-up (P=0.01) and pathCR patients had a longer OS than <pathCR patients (P=0.0006). However, in the SCC group OS or proportion alive did not differ significantly between pathCR and <pathCR patients (P>or=0.05). In the ACA group, a greater portion of <pathCR patients (32%) than pathCR patients (16%) had distant metastases (P=0.02) and the distant metastases-free survival of pathCR patients was longer than that of <pathCR patients (P=0.0012). In the SCC group, the proportion or time to distant-metastases did not differ significantly. Pretreatment clinical stage did not correlate with pathologic response for either histology.
The results of the current study suggest that the clinical biology of SCC and ACA is different after CTRT. An investigation of molecular and patient genetics is needed to improve therapy.
本研究检验了以下假设,即局部食管癌患者术前放化疗(CTRT)后的临床结局取决于组织学类型。
作者将患者按腺癌(ACA)或鳞状细胞癌(SCC)进行分层,并比较了术前CTRT后达到病理完全缓解(pathCR)和未达到pathCR的患者的总生存期(OS)及失败模式。对ACA和SCC患者的基线临床分期与治疗后病理反应之间的相关性进行了分析。
在接受术前CTRT的235例患者中,42例(18%)为SCC,193例(82%)为ACA。在ACA组中,56例患者(29%)达到pathCR,在SCC组中,13例患者(31%)达到pathCR。在ACA组中,最后一次随访时,达到pathCR的患者比例(n = 44;79%)高于未达到pathCR的患者(n = 82;60%)(P = 0.01),且pathCR患者的OS长于未达到pathCR的患者(P = 0.0006)。然而,在SCC组中,pathCR和未达到pathCR的患者之间的OS或存活比例无显著差异(P≥0.05)。在ACA组中,未达到pathCR的患者中发生远处转移的比例(32%)高于达到pathCR的患者(16%)(P = 0.02),且pathCR患者的无远处转移生存期长于未达到pathCR的患者(P = 0.0012)。在SCC组中,远处转移的比例或发生时间无显著差异。对于两种组织学类型,治疗前临床分期与病理反应均无相关性。
本研究结果表明,CTRT后SCC和ACA的临床生物学特性不同。需要对分子和患者遗传学进行研究以改进治疗方法。